Skip to main content

Advertisement

SpringerLink
Log in

Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinoma—A case report

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Therapeutic modalities for incompletely resected pancreatic carcinoma are rare. Effective treatment must not only prolong the period of palliation but also limit the adverse sequelae of the Whipple procedure so as not to compromise the quality of the remaining life span. New treatments include the use of gemcitabine and type I interferons. We treated a patient with incomplete resection of a pancreatic tumor with two cycles of gemcitabine (1000 mg/m2) and cisplatinum (50 mg/m2) followed by radiotherapy (45 Gy/5 weeks) combined with interferon-beta (three times a week/5 × 106 IU). Two small liver metastases occurred subsequently. In all, four cycles of gemcitabine/cisplatinum were delivered. The patient lived at least 9 months with stable metastatic liver disease and local control. He had no acute toxic reactions except for a decrease in the leukocyte count, no long-term side effects, and a satisfactory quality of life. A regimen of sequential gemcitabine/cisplatinum and radiotherapy in combination with interferon-beta deserves further consideration as therapy for pancreatic carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Howard JM, Jordan GL. Cancer of the pancreas.Curr Probl Cancer. 1977;2:1–52.

    Article  Google Scholar 

  2. Brooks JR. Cancer of the pancreas. In: Brooks JR, ed.Surgery of the Pancreas. Philadelphia: WB Saunders; 1983:263–298.

    Google Scholar 

  3. Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas.Cancer. 1973;32:1341–1345.

    Article  PubMed  CAS  Google Scholar 

  4. Moertel CG, Childs DS, Reitenmeier RJ, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.Lancet. 1969; 2:865–867.

    Article  PubMed  CAS  Google Scholar 

  5. Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.Cancer, I. 5th ed. Philadelphia: Lippincott-Raven; 1997:1054–1087.

    Google Scholar 

  6. Rosewicz S, Weder M, Kaiser A, Riecken EO. Antiproliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes.Gut. 1996;39:255–261.

    Article  PubMed  CAS  Google Scholar 

  7. Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.Cancer Res. 1996;56: 1083–1090.

    PubMed  CAS  Google Scholar 

  8. Sparano JA, Lipsitz S, Wadler S, et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292 1996.Am J Clin Oncols. 1996;19:546–551.

    Article  PubMed  CAS  Google Scholar 

  9. Recchia F, Sica G, Casucci D, Rea S, Gulino A, Frati L. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.Am J Clin Oncol. 1998;21:275–278.

    Article  PubMed  CAS  Google Scholar 

  10. Busch M, Rave-Fränk M, Franke T, Dühmke E. Effect of combined natural human beta-interferon and radiation on human tumor cells.Onkologie. 1996;19:501–504.

    Article  Google Scholar 

  11. McDonald S, Chang AY, Rubin P, et al. Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer.Int J Radiat Oncol Biol Phys. 1993; 27:613–619.

    PubMed  CAS  Google Scholar 

  12. Friedrich R, Wildfang I, Schnalke D, Schmoll HJ, Emminger A. Intralesional beta-interferon therapy and low dose radiotherapy (20Gy) in the treatment of refractory metastasis from solid tumours.J Cancer Res Clin Oncol. 1992;18:104.

    Google Scholar 

  13. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma.Ann Surg. 1979;189:205–208.

    Google Scholar 

  14. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads) + 5-fluorouracil, and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study.Cancer. 1981;48:1705–1710.

    Article  PubMed  CAS  Google Scholar 

  15. Bruckner HW, Kalnicki S, Dalton J, et al. Survival after combined modality therapy for pancreatic cancer.J Clin Gastroenterol. 1993;16:199–203.

    Article  PubMed  CAS  Google Scholar 

  16. Moertel CG, Gunderson LL, Mailliard JA, et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma.J Clin Oncol. 1994;12:21–27.

    PubMed  CAS  Google Scholar 

  17. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol. 1997;15:2403–2413.

    PubMed  CAS  Google Scholar 

  18. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.Ann Oncol. 1996;7:347–353.

    PubMed  CAS  Google Scholar 

  19. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: back to the future.Int J Radiat Oncol Biol Phys. 1998;42:59–63.

    PubMed  CAS  Google Scholar 

  20. Rougier P, Zarba JJ, Ducreux M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.Ann Oncol. 1993;4:333–336.

    PubMed  CAS  Google Scholar 

  21. Wils JA, Kok T, Wagener DJ, Selleslags J, Duez N. Activity of cisplatin in adenocarcinoma of the pancreas.Eur J Cancer. 1993;29:203–204.

    Article  Google Scholar 

  22. Rothman H, Cantrell JE Jr, Lokich J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program Study.Cancer. 1991;68: 264–268.

    Article  PubMed  CAS  Google Scholar 

  23. Dougherty JB, Kelsen D, Kemeny N, Magill G, Botet J, Niedzwiecki D. Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine.Natl Cancer Inst. 1989; 81:1735–1738.

    Article  CAS  Google Scholar 

  24. Kelsen D, Hudis C, Niedzwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.Cancer. 1991;68:965–969.

    Article  PubMed  CAS  Google Scholar 

  25. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.Semin Oncol. 1997;24:8–16.

    CAS  Google Scholar 

  26. Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterisation and molecular cloning.Cell. 1994;77:391–400.

    Article  PubMed  CAS  Google Scholar 

  27. Furue H. Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma.Gan To Kagaku Ryoho. 1985;12:1625–1629.

    PubMed  CAS  Google Scholar 

  28. Watanabe T, Fuchimoto S, Iwagaki H, et al. Anti-proliferative effect of combined tumour necrosis factor-alpha and interferon-alpha on human pancreatic cancer in vitro and in vivo.Anticancer Res. 1993;13:1501–1505.

    PubMed  CAS  Google Scholar 

  29. Matsubara N, Fuchimoto S, Orita K. Antiproliferative effects of natural human tumor necrosis factor-alpha, interferon-alpha, and interferon-gamma on human pancreatic carcinoma cell lines.Int J Pancreatol. 1991;8:235–243.

    PubMed  CAS  Google Scholar 

  30. Sarosy GA, Brown TD, Von Hoff DD, et al. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.Cancer Res. 1986;46:5368–5371.

    PubMed  CAS  Google Scholar 

  31. Knuth A, Bernhard H, Klein O, Meyer zum Buschenfelde KH. Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.Semin Oncol. 1992;19:211–214.

    PubMed  CAS  Google Scholar 

  32. John WJ, Flett MQ. Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma.Am J Clin Oncol. 1998;21:147–150.

    Article  PubMed  CAS  Google Scholar 

  33. Pazdur R, Ajani JJ, Abbruzzese JL, et al. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.Cancer. 1992;70:2073–2076.

    Article  PubMed  CAS  Google Scholar 

  34. Moore DF Jr, Pazdur R, Sugarman S, et al. Pilot phase II trial of 13-cis-retinoic acid and interferonalpha combination therapy for advanced pancreatic adenocarcinoma.Am J Clin Oncol. 1995;18: 525–527.

    Article  PubMed  Google Scholar 

  35. Tanaka N, Ohoida J, Matuno T, et al. Response of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment.Anticancer Res. 1994;14:2739–2742.

    PubMed  CAS  Google Scholar 

  36. Cappelli R, Gotti G. The locoregional treatment of neoplastic ascites with interferon-beta.Recenti Prog Med. 1992;83:82–84.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Strahlentherapie und Radioonkologie Klinikum Großhadern, Ludwig-Maximilians-Universität, Marchioninistraße 15, D 81377, Munich, Germany

    Martin Busch M.D., Ralf Wilkowski M.D., Moshe Schaffer M.D. & Eckhart Dühmke M.D.

Authors
  1. Martin Busch M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf Wilkowski M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Moshe Schaffer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eckhart Dühmke M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Busch, M., Wilkowski, R., Schaffer, M. et al. Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinoma—A case report. Adv Therapy 17, 133–139 (2000). https://doi.org/10.1007/BF02853154

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02853154

Keywords

Search

Navigation